Clinical Trials Logo
  1. Home
  2. Idiopathic Hypersomnia
  3. NCT03542851

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia — ARISE2  

Idiopathic Hypersomnia Clinical Trial

Official title:
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

Clinical Trial Summary

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.

Clinical Trial Description

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia (IH). The objectives of this study are two-fold: 1) To evaluate the efficacy of BTD-001 in subjects with IH as reflected by changes in cognitive, sleep, functional, and quality-of-life measures and 2) To characterize the safety and tolerability of oral BTD-001 administered to subjects with IH. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03542851
Study type Interventional
Source Balance Therapeutics
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 29, 2018
Completion date May 28, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04026958 - Clarithromycin Mechanisms in Hypersomnia Syndromes Phase 2
Completed NCT02512588 - A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Phase 2
Completed NCT01183312 - Flumazenil for the Treatment of Primary Hypersomnia Phase 1/Phase 2
Completed NCT03597555 - Sodium Oxybate in Idiopathic Hypersomnia Phase 2/Phase 3
Completed NCT03356938 - The Role of the Circadian System in Neurological Sleep-wake Disorders N/A
Completed NCT03533114 - A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Phase 3
Completed NCT05156047 - A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Phase 3
Enrolling by invitation NCT05371483 - Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
Not yet recruiting NCT06252571 - a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial Phase 2
Completed NCT04827329 - Anesthetic Management of Patients With Chronic Sleep Disorders
Not yet recruiting NCT06457945 - Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions N/A
Recruiting NCT05875974 - Ph4 PSG Combined JZP258-407 Phase 4
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT01146600 - Clarithromycin for the Treatment of Hypersomnia Phase 2
Recruiting NCT04330963 - International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
Completed NCT04091438 - A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia Phase 1
Recruiting NCT05615584 - Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence N/A
Recruiting NCT05837091 - Low Sodium Oxybate in Patients With Idiopathic Hypersomnia Phase 4
Recruiting NCT05321355 - Mainz Register of Patients With Sleep Disorders
Active, not recruiting NCT05668754 - Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH Phase 2